3Beksac M, Arslan O, Koc H, et al. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia[J].Med Oncol, 1998, 15(3) : 183 - 190. 被引量：1
4Vogler WR, Velez- Garcia E, Weiner RS, et al. A phase Ⅲ trial comparing idarubicin and daunorubicin in combination with cytambine in acute myelogenous leukemia: a Southeastem Cancer Study Group Study[J]. J Clin Oncol, 1992, 10(7):1103-1111. 被引量：1
5Wiemik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia[J]. Blood, 1992, 79(2):313 -319. 被引量：1
6Benton E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagaosed acute myelogenous leukemia[J]. Blood, 1991,77(8): 1666 - 1674. 被引量：1
7Mandelli F, Petti MC, Ardla A, et al. A randomised clinical trial comparing idambiein and eytarabine to daunorubicin and cytarobine in the treatment of acute non - lymphoid leukaemia. A muhicentric study from the Italian Co -operative Group GIMEMA[J]. Eur J Cancer, 1991,27(6) :750-755. 被引量：1
8Wiernik PH, Case DC Jr, Periman PO, et al. A multiceuter trial of cytarabine plus idarubicin or dannorubicin as induction therapy for adult nordymphocytic leukemia[J]. Semin Oncol, 1989,16(Suppl 2):25 - 29. 被引量：1
3Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol, 2003 ;21:4642 -4649. 被引量：1
4Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998 ;92 : 2322 - 2333. 被引量：1
5Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 1991 ;77 : 1666 -1674. 被引量：1
6Koistinm P, Raty R, Itala M, et al. Long-term outcome of intensive chemotherapy for adults with de nono acute myeloid leukemia (AML) : the nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol, 2007 ;78:477 -486. 被引量：1
7No authors listed. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol, 1998 ;103:100 - 109. 被引量：1
8Flasshove M, Meusers P, Schutte J, et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol, 2000 ;79:533 -542. 被引量：1
9Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies[J]. Leukemia, 2004, 18(1): 1. 被引量：1
10CHESON B D,BENNETT J M,KOPECKY K J,et al.Revised recommendations of the International Working Group for diagnosis.standardization of response criteria,treatment outcomes,and reporting standards for therapeutic trials in acute myeloid leukemia[J].J Clin Oncol,2003,21:4642-4649. 被引量：1
